Industry5 min read
Orforglipron Beats Oral Semaglutide: ACHIEVE-3 Data
The first head-to-head of two GLP-1 pills is out: orforglipron beat oral semaglutide on blood sugar and weight — but at a steeper GI cost.
Peptide News & Analysis
FDA actions, trial readouts, vendor coverage and pricing reports — curated for peptide buyers and clinicians.
Daily Peptide News
New articles delivered to your inbox every morning. Free.
Latest News
Regulatory7 min read
FDA Peptide Panel: Members Sell BPC-157, TB-500
AP flagged FDA's peptide panel for members who sell BPC-157 and TB-500. Here's how the July 23-24 vote actually broke down — 6 of 7 recommended.
Industry7 min read
Medicare GLP-1 Bridge Live: Who Gets the $50 Copay
Medicare's GLP-1 Bridge went live July 1 with a $50 copay — but only ~3.8M qualify, retatrutide isn't covered, and the copay has a catch.
Industry7 min read
Bofanglutide: Biweekly GLP-1 Beats Semaglutide
A 272-patient phase 2b trial found biweekly bofanglutide cut HbA1c more than semaglutide. Here's what the every-2-week GLP-1 means for buyers.
Regulatory5 min read
FDA Staff: No Compounding for BPC-157, TB-500, 5 More
FDA scientists recommend against adding BPC-157, TB-500, MOTS-c and 4 more to the compounding list before the July 23 vote. What it means for buyer access.
Industry6 min read
Viking's VK3019: New Amylin Drug Enters Trials
Viking started Phase 1 of VK3019, an amylin-calcitonin drug for weight loss. What DACRA means and the amylin peptides you can buy now.
Vendors1 min read
Is Southern Aminos Legit? Review, COAs & Prices
A US research-peptide vendor with batch-conformity testing and QR-coded COAs. What they carry and where to source the same compounds cheaper.
Vendors1 min read
GenPeptide Review
GenPeptide is a US research-peptide vendor with searchable HPLC/MS COAs and a GLP-1 kit builder. What they carry and where to source the same compounds.
Industry6 min read
One Person Got Retatrutide Early. Here's the Catch
The FDA granted one 79-year-old compassionate-use access to retatrutide. Here's why there's no legal prescription route — and where buyers source it.
Industry6 min read
Quintuple Agonist Beats Retatrutide in Rats: VRX-0075
A 5-receptor obesity peptide, VRX-0075, beat retatrutide for weight loss in obese rats at ADA 2026. What the data means and what you can buy now.
Regulatory5 min read
FDA Peptide Vote Results: What Buyers Need to Know
FDA panel backed BPC-157, TB-500, KPV, MOTS-c, Semax and Epitalon; DSIP rejected. What the results actually change for access — and what they don't.
Industry5 min read
Aleniglipron: The Next Oral GLP-1 Pill (And What to Buy Now)
Structure's aleniglipron hit ~16% weight loss as a once-daily pill at ADA 2026 — but it's years from pharmacy shelves. Here's what you can access today.
Vendors3 min read
Swiss Chems Review: Nootropic & Oral Peptides
Where to buy nootropic, oral, and novel research peptides — Noopept, Dihexa, NSI-189, 5-Amino-1MQ, SLU-PP-332 — from Swiss Chems, plus a 10% code.
Pricing6 min read
How to Buy Peptides in Bulk & Save
Buying more vials for your own multi-month protocol can cut your $/mg. How volume tiers, coupon stacking, and stability windows actually work.
Regulatory4 min read
FDA Hits 25 More Telehealth GLP-1 Sellers
FDA posted 25 new warning letters June 16 to telehealth firms over compounded semaglutide and tirzepatide claims. What it signals and what's still legal.
Industry4 min read
BELIEVE Trial: GLP-1 Combo Keeps 92% Fat Loss
Bimagrumab plus semaglutide hit 22.1% weight loss with 92.8% from fat in the BELIEVE trial. What it means for muscle-preserving peptide stacks.
Industry4 min read
GLP-1 Users Walk 560 Fewer Steps a Day: ENDO 2026
A Fitbit study at ENDO 2026 found GLP-1 users moved less after starting treatment. What it means for muscle, results, and how to push back.
Industry5 min read
Enicepatide: Roche's CT-388 Hits 22.5% at ADA 2026
Roche's enicepatide (CT-388) hit 22.5% placebo-adjusted weight loss at ADA 2026. What the dual GLP-1/GIP data means for buyers right now.